Review Article
Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
Table 6
Phase 2 clinical trials of everolimus in colorectal cancer.
| | Study | Status | Results | NCT identifier |
| | Panitumumab, irinotecan, and everolimus as 2nd-line in wild-type KRAS | Recruiting | Pending | NCT01139138 | | Efficacy and safety of everolimus with advanced CRC who failed prior chemo- and targeted therapy | Completed | Pending | NCT00419159 | | Irinotecan, everolimus, and cetuximab in metastatic CRC with KRAS mutation | Recruiting | Pending | NCT01387880 | | RAD001, FOLFOX, and bevacizumab in treatment of colorectal cancer | Recruiting | Pending | NCT01047293 | | Bevacizumab and everolimus in mCRC as a 2nd-line therapy | Completed | Pending | NCT00597506 | | Phase 2 trial of RAD001 in refractory colorectal cancer | Completed | Pending | NCT00337545 | | RAD001 and AV-951 in metastatic CRC | Ongoing, not recruiting | Pending | NCT01058655 | | Safety study of rapamycin administered before and during radiotherapy to treat rectum cancer | Recruiting | Pending | NCT00409994 |
|
|
